Nikko Asset Management Americas Inc. Purchases Shares of 54,423 China Biologic Products Holdings Inc (NASDAQ:CBPO)

Nikko Asset Management Americas Inc. acquired a new position in China Biologic Products Holdings Inc (NASDAQ:CBPO) in the first quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 54,423 shares of the biopharmaceutical company’s stock, valued at approximately $4,966,000. Nikko Asset Management Americas Inc. owned 0.14% of China Biologic Products as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the stock. AdvisorNet Financial Inc acquired a new stake in shares of China Biologic Products during the 4th quarter valued at $57,000. Cutler Group LP boosted its stake in shares of China Biologic Products by 58.4% during the 4th quarter. Cutler Group LP now owns 1,356 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 500 shares during the period. Amundi Pioneer Asset Management Inc. boosted its stake in shares of China Biologic Products by 79.9% during the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 2,100 shares of the biopharmaceutical company’s stock valued at $159,000 after buying an additional 933 shares during the period. Legal & General Group Plc boosted its stake in shares of China Biologic Products by 25.2% during the 3rd quarter. Legal & General Group Plc now owns 2,357 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 475 shares during the period. Finally, Quantamental Technologies LLC acquired a new stake in shares of China Biologic Products during the 1st quarter valued at $308,000. 36.29% of the stock is owned by hedge funds and other institutional investors.

A number of research analysts have recently weighed in on CBPO shares. ValuEngine upgraded shares of China Biologic Products from a “hold” rating to a “buy” rating in a report on Friday, March 1st. Credit Suisse Group set a $88.00 price target on shares of China Biologic Products and gave the company a “hold” rating in a report on Friday, March 8th. Jefferies Financial Group downgraded shares of China Biologic Products from a “hold” rating to an “underperform” rating and cut their price target for the company from $67.00 to $62.00 in a report on Monday, March 11th. BidaskClub upgraded shares of China Biologic Products from a “hold” rating to a “buy” rating in a report on Friday, April 5th. Finally, Zacks Investment Research upgraded shares of China Biologic Products from a “strong sell” rating to a “hold” rating in a report on Monday, May 13th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company. China Biologic Products currently has a consensus rating of “Hold” and a consensus price target of $78.00.

CBPO traded up $0.69 during trading on Friday, hitting $91.00. The stock had a trading volume of 126,100 shares, compared to its average volume of 224,535. The company has a market capitalization of $3.58 billion, a PE ratio of 22.64, a price-to-earnings-growth ratio of 4.74 and a beta of 1.28. China Biologic Products Holdings Inc has a 12 month low of $60.08 and a 12 month high of $107.44.

China Biologic Products (NASDAQ:CBPO) last announced its earnings results on Friday, May 10th. The biopharmaceutical company reported $1.11 EPS for the quarter, topping the consensus estimate of $0.99 by $0.12. The firm had revenue of $129.78 million for the quarter, compared to the consensus estimate of $119.50 million. China Biologic Products had a net margin of 27.71% and a return on equity of 8.81%. During the same quarter last year, the firm posted $1.21 EPS. As a group, equities research analysts forecast that China Biologic Products Holdings Inc will post 3.87 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This story was first posted by Sundance Herald and is the property of of Sundance Herald. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://sundanceherald.com/2019/05/24/nikko-asset-management-americas-inc-buys-shares-of-54423-china-biologic-products-holdings-inc-cbpo.html.

About China Biologic Products

China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.

See Also: What are popular green investing opportunities?

Institutional Ownership by Quarter for China Biologic Products (NASDAQ:CBPO)

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply